| Description |
Lilotomab (HH1) is a murine anti-CD37 monoclonal antibody. Lilotomab reduces clonogenic survival. Lilotomab shows anti-tumor activity[1].
|
| Related Catalog |
|
| Target |
CD37[1]
|
| In Vitro |
Lilotomab (0-40 µg/mL; 12 days) 降低 DOHH2 和 Ramos 细胞的克隆形成存活率[1]。 Lilotomab (40 µg/mL; 18 h) 诱导 DOHH2 细胞轻微凋亡[1]。 Apoptosis Analysis[1] Cell Line: Ramos, DOHH2, Rec-1 cells Concentration: 40 µg/mL Incubation Time: 18 h Result: Induced apoptosis in DOHH2 cells.
|
| In Vivo |
Lilotomab (0.5 mg/kg；i.v.；一次) 抑制小鼠肿瘤生长[1]。 Animal Model: SCID mice (DOHH2 cell xenografts)[1] Dosage: 0.5 mg/kg Administration: I.v.; once Result: Inhibited tumor growth and increased mouse survival.
|
| References |
[1]. Malenge MM, et al. 177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma. J Nucl Med. 2020 Oct;61(10):1468-1475.
|
